{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Front-line&page=2", "query": { "condition": "Front-line", "page": 2 }, "page_size": 10 }, "pagination": { "page": 2, "page_size": 10, "total_count": 10, "total_pages": 1, "next_page_url": null, "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Front-line&page=1&page_size=10" }, "source": "remote", "last_synced_at": "2026-09-29T14:36:01.633Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT01075048", "title": "ARQ 197 in Combination With Chemotherapy in Patients With Metastatic Colorectal Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Metastatic Colorectal Cancer" ], "interventions": [ { "name": "Tivantinib", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" }, { "name": "Cetuximab", "type": "DRUG" }, { "name": "Irinotecan", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Daiichi Sankyo", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 131, "start_date": "2010-01-26", "completion_date": "2015-02-20", "has_results": true, "last_update_posted_date": "2021-04-08", "last_synced_at": "2026-09-29T14:36:01.633Z", "location_count": 24, "location_summary": "Beverly Hills, California • Encinitas, California • Fountain Valley, California + 21 more", "locations": [ { "city": "Beverly Hills", "state": "California" }, { "city": "Encinitas", "state": "California" }, { "city": "Fountain Valley", "state": "California" }, { "city": "Riverside", "state": "California" }, { "city": "Fort Collins", "state": "Colorado" } ], "official_url": "https://clinicaltrials.gov/study/NCT01075048" }, { "nct_id": "NCT00814086", "title": "Cisplatin and Paclitaxel in Treating Patients With Stage IIB, Stage IIC, Stage III, or Stage IV Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cavity Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Chemotherapeutic Agent Toxicity", "Endometrial Adenocarcinoma", "Fallopian Tube Carcinoma", "Gastrointestinal Complication", "Malignant Ovarian Mixed Epithelial Tumor", "Neurotoxicity Syndrome", "Ovarian Brenner Tumor", "Ovarian Clear Cell Cystadenocarcinoma", "Ovarian Mucinous Cystadenocarcinoma", "Ovarian Serous Cystadenocarcinoma", "Primary Peritoneal Carcinoma", "Stage II Ovarian Cancer", "Stage III Ovarian Cancer", "Stage IV Ovarian Cancer", "Undifferentiated Ovarian Carcinoma" ], "interventions": [ { "name": "Paclitaxel", "type": "DRUG" }, { "name": "Cisplatin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Gynecologic Oncology Group", "sponsor_class": "NETWORK", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": null, "sex": "FEMALE", "summary": "Female only" }, "enrollment_count": 23, "start_date": "2009-02", "completion_date": null, "has_results": false, "last_update_posted_date": "2014-12-31", "last_synced_at": "2026-09-29T14:36:01.633Z", "location_count": 7, "location_summary": "Chicago, Illinois • Iowa City, Iowa • Camden, New Jersey + 4 more", "locations": [ { "city": "Chicago", "state": "Illinois" }, { "city": "Iowa City", "state": "Iowa" }, { "city": "Camden", "state": "New Jersey" }, { "city": "Columbus", "state": "Ohio" }, { "city": "Tulsa", "state": "Oklahoma" } ], "official_url": "https://clinicaltrials.gov/study/NCT00814086" }, { "nct_id": "NCT00067028", "title": "Clofarabine Combinations in Relapsed/Refractory Acute Myeloid Leukemia (AML), Myelodysplastic Syndromes (MDS) and Myeloid Blast Phase Chronic Myeloid Leukemia (CML)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Acute Myeloid Leukemia", "Myelodysplastic Syndrome", "Chronic Myeloid Leukemia" ], "interventions": [ { "name": "Clofarabine 40mg/m^2", "type": "DRUG" }, { "name": "Idarubicin 10mg/m^2", "type": "DRUG" }, { "name": "Ara-C 0.75 g/m^2", "type": "DRUG" }, { "name": "Clofarabine 22.5mg/m^2", "type": "DRUG" }, { "name": "Ara-C 1 g/m^2", "type": "DRUG" }, { "name": "Idarubicin 6 mg/m^2", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "M.D. Anderson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "59 Years", "sex": "ALL", "summary": "18 Years to 59 Years" }, "enrollment_count": 116, "start_date": "2003-12", "completion_date": "2013-06", "has_results": true, "last_update_posted_date": "2020-12-08", "last_synced_at": "2026-09-29T14:36:01.633Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT00067028" }, { "nct_id": "NCT03113422", "title": "Phase II Venetoclax, Obinutuzumab and Bendamustine in High Tumor Burden Follicular Lymphoma as Front Line Therapy", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Follicular Lymphoma", "Non-Hodgkin's Lymphoma Follicular", "Non-Hodgkin's Lymphoma, Adult High Grade" ], "interventions": [ { "name": "Induction Venetoclax", "type": "DRUG" }, { "name": "Maintenance Venetoclax", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "PrECOG, LLC.", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 56, "start_date": "2017-12-27", "completion_date": "2023-01-06", "has_results": true, "last_update_posted_date": "2025-05-23", "last_synced_at": "2026-09-29T14:36:01.633Z", "location_count": 10, "location_summary": "Atlanta, Georgia • Baltimore, Maryland • Rochester, Minnesota + 7 more", "locations": [ { "city": "Atlanta", "state": "Georgia" }, { "city": "Baltimore", "state": "Maryland" }, { "city": "Rochester", "state": "Minnesota" }, { "city": "St Louis", "state": "Missouri" }, { "city": "New Brunswick", "state": "New Jersey" } ], "official_url": "https://clinicaltrials.gov/study/NCT03113422" }, { "nct_id": "NCT04416451", "title": "A Phase II Study Using Rituximab Plus Venetoclax in the Front Line Treatment of Marginal Zone Lymphoma", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Marginal Zone Lymphoma" ], "interventions": [ { "name": "Rituximab", "type": "DRUG" }, { "name": "Venetoclax", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Memorial Sloan Kettering Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 6, "start_date": "2021-05-04", "completion_date": "2027-06", "has_results": false, "last_update_posted_date": "2026-07-06", "last_synced_at": "2026-09-29T14:36:01.633Z", "location_count": 8, "location_summary": "Duarte, California • Basking Ridge, New Jersey • Middletown, New Jersey + 5 more", "locations": [ { "city": "Duarte", "state": "California" }, { "city": "Basking Ridge", "state": "New Jersey" }, { "city": "Middletown", "state": "New Jersey" }, { "city": "Montvale", "state": "New Jersey" }, { "city": "Commack", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT04416451" }, { "nct_id": "NCT02655016", "title": "A Study of Niraparib (GSK3985771) Maintenance Treatment in Participants With Advanced Ovarian Cancer Following Response on Front-Line Platinum-Based Chemotherapy", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Ovarian Neoplasms" ], "interventions": [ { "name": "Niraparib", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Tesaro, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 733, "start_date": "2016-07-11", "completion_date": "2026-05-29", "has_results": true, "last_update_posted_date": "2026-03-10", "last_synced_at": "2026-09-29T14:36:01.633Z", "location_count": 47, "location_summary": "Tempe, Arizona • Tucson, Arizona • San Francisco, California + 41 more", "locations": [ { "city": "Tempe", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" }, { "city": "San Francisco", "state": "California" }, { "city": "San Francisco", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT02655016" }, { "nct_id": "NCT03361852", "title": "Personalized Neoantigen Cancer Vaccine + Pembrolizumab After Rituximab for Follicular Lymphoma", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Follicular Lymphoma" ], "interventions": [ { "name": "Rituximab", "type": "DRUG" }, { "name": "Neo Vax", "type": "BIOLOGICAL" }, { "name": "Pembrolizumab", "type": "DRUG" } ], "intervention_types": [ "DRUG", "BIOLOGICAL" ], "sponsor": "Dana-Farber Cancer Institute", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 20, "start_date": "2022-03-14", "completion_date": "2033-12-26", "has_results": false, "last_update_posted_date": "2026-03-25", "last_synced_at": "2026-09-29T14:36:01.633Z", "location_count": 1, "location_summary": "Boston, Massachusetts", "locations": [ { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT03361852" }, { "nct_id": "NCT03733691", "title": "Ph 2 Maintenance Trial: Ixazomib vs Ixazomib-Lenalidomide for MM Patients", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Newly Diagnosed Multiple Myeloma" ], "interventions": [ { "name": "Ixazomib", "type": "DRUG" }, { "name": "Lenalidomide", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Oncotherapeutics", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "100 Years", "sex": "ALL", "summary": "18 Years to 100 Years" }, "enrollment_count": 19, "start_date": "2019-03-01", "completion_date": "2023-10-19", "has_results": false, "last_update_posted_date": "2023-10-25", "last_synced_at": "2026-09-29T14:36:01.633Z", "location_count": 1, "location_summary": "West Hollywood, California", "locations": [ { "city": "West Hollywood", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT03733691" }, { "nct_id": "NCT05786040", "title": "Tafasitamab and Rituximab for Front-Line Treatment of Post-Transplant Lymphoproliferative Disorder", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Monomorphic B-Cell Post-Transplant Lymphoproliferative Disorder", "Polymorphic Post-Transplant Lymphoproliferative Disorder" ], "interventions": [ { "name": "Biopsy", "type": "PROCEDURE" }, { "name": "Biospecimen Collection", "type": "PROCEDURE" }, { "name": "Computed Tomography", "type": "PROCEDURE" }, { "name": "Positron Emission Tomography", "type": "PROCEDURE" }, { "name": "Rituximab", "type": "BIOLOGICAL" }, { "name": "Tafasitamab", "type": "BIOLOGICAL" } ], "intervention_types": [ "PROCEDURE", "BIOLOGICAL" ], "sponsor": "Timothy Voorhees", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 28, "start_date": "2023-03-23", "completion_date": "2027-12-31", "has_results": false, "last_update_posted_date": "2026-04-14", "last_synced_at": "2026-09-29T14:36:01.633Z", "location_count": 4, "location_summary": "New Brunswick, New Jersey • Hillsborough, North Carolina • Columbus, Ohio + 1 more", "locations": [ { "city": "New Brunswick", "state": "New Jersey" }, { "city": "Hillsborough", "state": "North Carolina" }, { "city": "Columbus", "state": "Ohio" }, { "city": "Salt Lake City", "state": "Utah" } ], "official_url": "https://clinicaltrials.gov/study/NCT05786040" }, { "nct_id": "NCT00358644", "title": "Study of Decitabine for Treatment of Older Patients With Acute Myeloid Leukemia (AML)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Acute Myeloid Leukemia" ], "interventions": [ { "name": "Decitabine", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Eisai Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "60 Years", "maximum_age": null, "sex": "ALL", "summary": "60 Years and older" }, "enrollment_count": 55, "start_date": "2005-03", "completion_date": "2008-12", "has_results": true, "last_update_posted_date": "2013-05-20", "last_synced_at": "2026-09-29T14:36:01.633Z", "location_count": 3, "location_summary": "Duarte, California • Los Angeles, California • St Louis, Missouri", "locations": [ { "city": "Duarte", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "St Louis", "state": "Missouri" } ], "official_url": "https://clinicaltrials.gov/study/NCT00358644" } ] }